Clinical trials: Pneumonitis
Kerosene Pneumonitis
Antibiotic Efficacy in Pneumonitis Following Paraffin (Kerosene) Ingestion in Children
Paraffin (kerosene) ingestion in the developing world accounts for a large number of visits to healthcare facilities, especially amongst children.
- Trial name
- NCT01253980
- Testing
- Amoxicillin
- Where
- South Africa
- Volunteers
- 74 people
- Sponsor
- University of Cape Town
Non-Small-Cell Lung Carcinoma
Trial of Image-Guided Adaptive Conformal Photon vs Proton Therapy, With Concurrent Chemotherapy, for Locally Advanced Non-Small Cell Lung Carcinoma: Treatment Related Pneumonitis and Locoregional Recurrence
The goal of this clinical research study is to learn if, compared with regular x-ray radiation, proton radiation reduces the risk of developing, treatment-related pneumonitis (TRP) or tumor recurrence (the tumor coming back in…
- Trial name
- NCT00915005
- Testing
- Photon Therapy, Proton Therapy, Paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 275 people
- Sponsor
- M.D. Anderson Cancer Center
Cystic Fibrosis
NAC Phase IIB: A Multi-Center, Phase IIB, Randomized, Placebo-controlled, Double-Blind Study Of The Effects Of N-Acetylcysteine On Redox Changes and Lung Inflammation In Cystic Fibrosis Patients
This Phase IIB proof-of-concept study would examine the effects of an investigational product called N-acetylcysteine (NAC) on the basic processes that cause inflammation in CF lung disease.
- Trial name
- NCT00809094
- Testing
- N-acetylcysteine (NAC)
- Where
- 11 sites in United States
- Volunteers
- 70 people
- Sponsor
- Stanford University
Cystic Fibrosis
IL-17 Neutrophils in CF Lung Inflammation
The purpose of this study is to determine whether IL-17 polymorphonuclear leukocytes (PMNs) are central to the disease pathology in CF.
- Trial name
- NCT02025829
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University Hospitals Cleveland Medical Center
Idiopathic Pulmonary Fibrosis
A 2-Part, Phase 2 Open-label and Crossover Study of Belumosudil for Treatment of Idiopathic Pulmonary Fibrosis
This Phase 2 study is to be conducted to evaluate the safety, tolerability, and activity of 400 mg of belumosudil orally (PO) once-daily (QD) compared to Best Supportive Care (BSC) in male and postmenopausal/surgically sterilized…
- Trial name
- NCT02688647
- Testing
- Belumosudil, BSC
- Where
- 10 sites in United States
- Volunteers
- 76 people
- Sponsor
- Kadmon Corporation, LLC
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Tocilizumab for Patients With Cancer and COVID-19 Disease
This phase II expanded access trial will study how well tocilizumab works in reducing the serious symptoms including pneumonitis (severe acute respiratory distress) in patients with cancer and COVID-19.
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Pneumonia, Pneumonitis
- Trial name
- NCT04370834
- Testing
- Tocilizumab
- Where
- 5 sites in United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Gastroesophageal Reflux, Asthma
Elucidation of Acid-Induced Pulmonary Inflammation
This study will evaluate how heartburn may lead to different types of inflammation in one's airways. Additionally, the study will determine whether aggressive treatment of heartburn results in improvement in both symptoms of…
- Trial name
- NCT00361972
- Testing
- lansoprazole
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Utah
Interstitial Pneumonitis, Polymyositis
Investigation in Myositis-associated Pneumonitis of Prednisolone And Concomitant Tacrolimus
The purpose of the study is to evaluate the efficacy and safety of the combination treatment of tacrolimus and corticosteroid in polymyositis/dermatomyositis patients with interstitial pneumonitis with comparison against…
- Conditions
- Interstitial Pneumonitis, Polymyositis, Dermatomyositis
- Trial name
- IMPPACT (NCT00504348)
- Testing
- Tacrolimus
- Where
- 11 sites in Japan
- Volunteers
- 25 people
- Sponsor
- Tokyo Medical and Dental University
Idiopathic Pulmonary Fibrosis, Fibrosis
A Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis
This is a Phase 2, multicenter, multinational, randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, pharmacokinetics (PK), quality of life and exploratory pharmacodynamics (PD) of two treatment…
- Conditions
- Idiopathic Pulmonary Fibrosis, Fibrosis, Idiopathic Interstitial Pneumonias, Pathologic Processes
- Trial name
- NCT03142191
- Testing
- CC-90001
- Where
- 112 sites in United States, Australia and 11 more
- Volunteers
- 138 people
- Sponsor
- Celgene
Asthma
The Effect of Dupilumab on Lung Inflammation and Related Changes in Airway Volumes Detectable by Functional Respiratory Imaging in Patients With Moderate-severe Asthma
Primary Objective: To assess the effect of dupilumab on lung inflammation and related changes in airway volumes detectable by functional respiratory imaging Secondary Objective: To evaluate the effect of dupilumab at Week 24 on…
- Trial name
- VESTIGE (NCT04400318)
- Testing
- Dupilumab
- Where
- 65 sites in United States, Bulgaria and 11 more
- Volunteers
- 109 people
- Sponsor
- Sanofi
Respiratory Failure, Respiratory Infection
Avoiding Neuromuscular Blockers to Reduce Complications
The goal of this study to evaluate whether eliminating the use of non-depolarizing neuromuscular blocking agents (NMBA) for maintenance of general anesthesia reduces postoperative pulmonary complications in higher risk patients.
- Conditions
- Respiratory Failure, Respiratory Infection, Aspiration Pneumonia, Pneumonitis
- Trial name
- NCT03962725
- Testing
- Neuromuscular Blocking Agents, Anesthetic Adjuncts
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Beth Israel Deaconess Medical Center
COPD
Chronic Obstructive Pulmonary Disease (COPD) Biomarker Identification Study
Chronic obstructive pulmonary disease (COPD) is a common inflammatory disease of the airway affecting approximately 10% of individuals aged 40 years or more with a smoking history.
- Trial name
- NCT01780298
- Where
- United Kingdom
- Volunteers
- 252 people, healthy volunteers welcome
- Sponsor
- Philip Morris Products S.A.
COVID-19, Lung Inflammation
Treat COVID-19 Patients With Regadenoson
More than 17 million people have been infected and more than 677K lives have been lost since the COVID-19 pandemic. Unfortunately, there is neither an effective treatment nor is there a vaccination for this deadly virus.
- Trial name
- NCT04606069
- Testing
- Regadenoson
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Maryland, Baltimore
Unresectable Stage III NSCLC
Mobile Devices to Detect Early Pneumonitis in Stage III NSCLC Patients on Durvalumab.
A study of whether mobile devices can improve the detection of pulmonary AEs (including pneumonitis) in stage III NSCLC patients post-CRT, while on durvalumab.
- Trial name
- ON TRAX (NCT04381494)
- Testing
- Multiparametric Mobile Technology
- Where
- 18 sites in United States
- Volunteers
- 40 people
- Sponsor
- AstraZeneca
Complication of Surgical Procedure, Acute Respiratory Failure, Adult
Prospective Evaluation of a RIsk Score for Postoperative Pulmonary COmPlications in Europe
Prospective Evaluation of a RIsk Score for postoperative pulmonary COmPlications in Europe (PERISCOPE) is a multi-centre, international observational study of a random-sample cohort of patients undergoing a nonobstetric…
- Conditions
- Complication of Surgical Procedure, Acute Respiratory Failure, Adult, Postoperative Respiratory Complications, Pulmonary Failure
- Trial name
- PERISCOPE (NCT01346709)
- Where
- 63 sites in Albania, Belgium and 19 more
- Volunteers
- 5,450 people
- Sponsor
- European Society of Anaesthesiology
Idiopathic Pulmonary Fibrosis
Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
To evaluate the safety and tolerability of pamrevlumab in participants with IPF, and the efficacy of pamrevlumab in slowing the loss of forced vital capacity (FVC) and the progression of IPF in these participants.
- Trial name
- NCT01890265
- Testing
- Pamrevlumab, Sub-Study: Pirfenidone, Sub-Study: Nintedanib
- Where
- 42 sites in United States, Australia and 5 more
- Volunteers
- 160 people
- Sponsor
- Kyntra Bio
Acute Lung Injury (ALI) Associated With COVID-19, Lung Inflammation Associated With COVID-19
TD-0903 for ALI Associated With COVID-19
This Phase 2 study will evaluate the efficacy, safety, pharmacodynamics and pharmacokinetics of inhaled TD-0903 compared with a matching placebo in combination with standard of care (SOC) in hospitalized patients with confirmed…
- Trial name
- NCT04402866
- Testing
- TD-0903
- Where
- 24 sites in United States, Brazil and 5 more
- Volunteers
- 235 people
- Sponsor
- Theravance Biopharma
Pulmonary Fibrosis
Supplemental Oxygen in Pulmonary Fibrosis
To enhance understanding of supplemental oxygen-its utility in and adoption by patients with pulmonary fibrosis-by examining how patients perceive it and by determining how perceptions and patient-centered outcome measures change…
- Trial name
- NCT01961362
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- National Jewish Health
Idiopathic Pulmonary Fibrosis
Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
This is a Phase 3 trial to evaluate the efficacy and safety of 30 milligrams (mg)/kilogram (kg) intravenous (IV) infusions of pamrevlumab administered every 3 weeks as compared to placebo in participants with Idiopathic Pulmonary…
- Trial name
- NCT04419558
- Testing
- Pamrevlumab
- Where
- 157 sites in United States, Argentina and 23 more
- Volunteers
- 372 people
- Sponsor
- Kyntra Bio
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT
This study assesses the safety and efficacy of bardoxolone methyl relative to placebo in patients with pulmonary hypertension to determine the recommended dose range, evaluate the change from baseline in 6-minute walk distance…
- Conditions
- Pulmonary Arterial Hypertension, Pulmonary Hypertension, Interstitial Lung Disease, Idiopathic Interstitial Pneumonia
- Trial name
- NCT02036970
- Testing
- Bardoxolone methyl
- Where
- 32 sites in United States, Germany
- Volunteers
- 166 people
- Sponsor
- Biogen